These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28463029)

  • 1. High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
    Hattori Y; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Oguchi T; Kanayama Y; Miyake H; Kato T; Takagi H; Hayashi M; Ito T; Shioura T; Takahashi N; Ishikawa H; Funahashi K; Ishiguro N
    Mod Rheumatol; 2018 Jan; 28(1):119-125. PubMed ID: 28463029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2019 Jan; 38(1):181-187. PubMed ID: 28940139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
    Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
    Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
    Lamers-Karnebeek FBG; Jacobs JWG; Radstake TRDJ; van Riel PLCM; Jansen TL
    Rheumatology (Oxford); 2019 Mar; 58(3):427-431. PubMed ID: 30383251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
    Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
    Shiozawa K; Yamane T; Murata M; Yoshihara R; Tsumiyama K; Imura S; Shiozawa S
    Arthritis Res Ther; 2016 Feb; 18():55. PubMed ID: 26922083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis.
    Hattori Y; Kida D; Kaneko A
    Mod Rheumatol; 2018 Mar; 28(2):242-248. PubMed ID: 28756710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
    Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
    Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept.
    Takemoto T; Takahashi N; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
    Clin Exp Rheumatol; 2020; 38(5):933-939. PubMed ID: 32083543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
    Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
    Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
    Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
    J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
    Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
    Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study.
    Ma JD; Wei XN; Zheng DH; Mo YQ; Chen LF; Zhang X; Li JH; Dai L
    Arthritis Res Ther; 2015 Oct; 17():289. PubMed ID: 26467222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
    Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.